ReviewBiosensors2025
Current Trends in In Vitro Diagnostics Using Surface-Enhanced Raman Scattering in Translational Biomedical Research.
Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress of surface-enhanced Raman scattering technology in tumor liquid biopsy.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoassays using surface-enhanced Raman scattering (SERS) are prosperous in disease diagnosis due to their excellent multiplexing ability, high sensitivity, and large dynamic range. Given the recent advancements in SERS immunoassays, this work provides a comprehensive overview, from fundamental principles to practical applications. An mRNA sensor utilizing Raman spectroscopy is a detection method that leverages the unique vibrational characteristics of mRNA molecules to identify and quantify their presence in a sample, often achieved through a technique called SERS, where specially designed nanoparticles amplify the Raman signal, allowing for the highly sensitive detection of even small amounts of mRNA. This review analyzes SERS assays used to detect RNA biomarkers, which show promise in cancer diagnostics and are being actively studied clinically. To selectively detect a specific mRNA sequence, a probe molecule (e.g., a DNA oligonucleotide complementary to the target mRNA) is attached to the SERS substrate, allowing the target mRNA to hybridize and generate a detectable Raman signal upon binding. Thus, the discussion includes proposals to enhance SERS immunoassay performance, along with future challenges and perspectives, offering concise, valid guidelines for platform selection based on application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.